GOSS Gossamer Bio Inc

In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Gossamer Bio (GOSS - Research Report), with a price target of $7.00. The company's shares opened today at $3.44.According to TipRanks, Argyrides is an analyst with an average return of -8.7% and a 41.07% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, BioMarin Pharmaceutical, and Albireo Pharma.Gossamer Bio has an analyst consensus of Strong Buy, with a price target consensus of $16.14, a 369.19% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.
https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-gossamer-bio-goss?utm_source=advfn.com&utm_medium=referral